A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcin
A phase 3 trial of MRG003, Pucotenlimab, Gemcitabine in nasopharyngeal carcinoma, run by Lepu Biopharma Co., Ltd., now recruiting.
Overview
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma is a phase 3 interventional study registered as NCT06976190 by Lepu Biopharma Co., Ltd., with 446 participants planned, started 2025-05-06 and due to reach its primary completion in 2029-05. Interventions recorded: MRG003 + Pucotenlimab, Gemcitabine, Docetaxel, or Capecitabine. Conditions listed: Recurrent or Metastatic Nasopharyngeal Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
Shares MRG003, Lepu Biopharma, Nasopharyngeal carcinoma, Docetaxel.
- TrialA Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN
Shares MRG003, Lepu Biopharma.
- TrialPucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
Shares Pucotenlimab, Lepu Biopharma.
- TrialMRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
Shares Pucotenlimab, Lepu Biopharma.
- TrialA Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)
Shares Nasopharyngeal carcinoma, Docetaxel, Gemcitabine.
- TrialA Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC
Shares Docetaxel, Gemcitabine.
- TrialA Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Shares Nasopharyngeal carcinoma, Gemcitabine.
- TrialA Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Shares Docetaxel, Gemcitabine.